Our story starts in 2013, with all of the founding fathers were working as scientist in the Radboudumc. From the frustration with inadequate treatments for CKD, a new plan, involving targeted nanoparticles, was born.
This plan got traction when we, by (happy) accident, found a peptide with remarkable qualities, including the much sought after targeting to the glomerulus.
This discovery was the start of an investigation that would take years, in which we looked into every aspect of the behavior of the peptide, developed new mRNAs and dived deep into the physics and chemistry of making nanoparticles.
With all that data in hand, we are now taking the next big step by starting up Mercurna, so we can turn this idea into a life-saving product.